个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

The role of E3 ubiquitin ligase HECTD3 in cancer and beyond

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Jiang, Qiuyun[1,2] * ; Li, Fubing[3] ; Cheng, Zhuo[1,2] ; Kong, Yanjie[4] ; Chen, Ceshi[1,2,5] ;
机构： [1]Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China [2]Kunming College of Life Science, University of the Chinese Academy of Sciences, Kunming 650204, China [3]Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510095, China [4]Institute of Translation Medicine, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China [5]KIZ‑CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China
出处：
DOI： 10.1007/s00018-019-03339-3
ISSN：

关键词： Ubiquitination HECTD3 Cancer Inhibitors

摘要：
Ubiquitin modification plays significant roles in protein fate determination, signaling transduction, and cellular processes. Over the past 2 decades, the number of studies on ubiquitination has demonstrated explosive growth. E3 ubiquitin ligases are the key enzymes that determine the substrate specificity and are involved in cancer. Several recent studies shed light on the functions and mechanisms of HECTD3 E3 ubiquitin ligase. This review describes the progress in the recent studies of HECTD3 in cancer and other diseases. We propose that HECTD3 is a potential biomarker and a therapeutic target, and discuss the future directions for HECTD3 investigations.

基金：
National Key R&D Program of China [2018YFC2000400]; National Nature Science Foundation of ChinaNational Natural Science Foundation of China [81830087, U1602221, 31771516, 81773149]; Shenzhen Municipal Government of China [KQTD20170810160226082]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 2 区 生物
小类 | 2 区 生化与分子生物学 2 区 细胞生物学
最新[2023]版：
大类 | 2 区 生物学
小类 | 2 区 生化与分子生物学 2 区 细胞生物学
JCR分区：
出版当年[2019]版：
Q1 CELL BIOLOGY Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
最新[2023]版：
Q1 CELL BIOLOGY Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者：
第一作者机构： [1]Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China [2]Kunming College of Life Science, University of the Chinese Academy of Sciences, Kunming 650204, China
通讯作者：
通讯机构： [1]Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China [2]Kunming College of Life Science, University of the Chinese Academy of Sciences, Kunming 650204, China [5]KIZ‑CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China
推荐引用方式(GB/T 7714)：
Jiang Qiuyun,Li Fubing,Cheng Zhuo,et al.The role of E3 ubiquitin ligase HECTD3 in cancer and beyond[J].CELLULAR AND MOLECULAR LIFE SCIENCES.2020,77(8):1483-1495.doi:10.1007/s00018-019-03339-3.
APA：
Jiang, Qiuyun,Li, Fubing,Cheng, Zhuo,Kong, Yanjie&Chen, Ceshi.(2020).The role of E3 ubiquitin ligase HECTD3 in cancer and beyond.CELLULAR AND MOLECULAR LIFE SCIENCES,77,(8)
MLA：
Jiang, Qiuyun,et al."The role of E3 ubiquitin ligase HECTD3 in cancer and beyond".CELLULAR AND MOLECULAR LIFE SCIENCES 77..8(2020):1483-1495

相关文献

[1]Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer. [2]Targeting ubiquitin conjugating enzyme UbcH5b by a triterpenoid PC3-15 from Schisandra plants sensitizes triple-negative breast cancer cells to lapatinib. [3]CUL7 promotes cancer cell survival through promoting Caspase-8 ubiquitination. [4]PD-1 inhibitors dependent CD8(+) T cells inhibit mouse colon cancer cell metastasis [5]Phase II clinical trial of metronomic oral capecitabine therapy combined with aromatase inhibitors in postmenopausal metastatic and recurrent breast cancer resistant to first-line aromatase inhibitors [6]Roles of RNF126 and BCA2 E3 ubiquitin ligases in DNA damage repair signaling and targeted cancer therapy [7]Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial. [8]Biological knowledge graph-guided investigation of immune therapy response in cancer with graph neural network [9]Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer [10]Targeting HECTD3-IKK alpha axis inhibits inflammation-related metastasis

资源点击量：82478 今日访问量：0 总访问量：681 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西山区金碧路157号